Study of AEF0217 for people with Down syndrome
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Down syndrome (full trisomy 21 or a translocation type, not mosaic).
- You need to be between 16 and 32 years old.
- A parent or caregiver must go with you to all visits and help you follow the study plan.
- You must be able to walk on your own and have enough vision and hearing for the tests.
- You cannot have epilepsy or a history of seizures (except one mild fever seizure more than 8 years ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the effects of a medication called AEF0217 in people with Down syndrome. It is for participants who have already completed an earlier study of AEF0217 and their caregivers.
This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.
This study aims to understand thinking and memory in adults with intellectual disabilities, including those with Down syndrome. Participants will complete language and thinking tests to help improve future care.
This study tests whether a supplement that boosts a natural substance called NAD (which helps cells work properly) can slow or stop memory loss in people with Down syndrome. You and your caregiver would visit a clinic for regular checkups and take the supplement daily.
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
This trial studies whether a GnRH hormone treatment can improve thinking and memory in people with Down syndrome. It also checks safety and whether the treatment affects brain-related changes seen on MRI.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.